A novel vascular stem cell product ANGICYTE for regenerative medicine

用于再生医学的新型血管干细胞产品ANGICYTE

• 批准号: 105380
• 金额: $ 26.92万
• 依托单位: VASCVERSA LTD
• 依托单位国家: 英国
• 项目类别: Study
• 财政年份: 2020
• 资助国家: 英国
• 起止时间: 2020 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=105380
• 关键词: novel; vascular; stem; cell; product

"VascVersa (Versatile Vascular Stem Cells for Regenerative Medicine)Cardiovascular diseases are the top cause of death worldwide. There is an urgent need to find new treatments to repair damaged blood vessels as current approaches are not optimal. At VascVersa, we are committed to develop innovative regenerative medicine, and we have optimised a consistent way to manufacture highly pure vascular stem cells from a sample of blood. Our unique method of generation produces a stem cell therapy product ANGICYTE, of top quality with higher purity and superior growth capacity, when compared to other available cell products.These vascular stem cells can be grown up in our laboratory to provide large numbers for treatment. As all tissue repair requires blood supply, ANGICYTE can be harnessed to target areas of blood vessel injury and promote repair of damaged blood vessels. We have experimental evidence that our Vascular stem cells can be used as a cellular therapy promoting new blood vessel formation. We are developing a novel cell therapy product ANGICYTE for regenerative medicine. In the first phase, we will use ANGICYTE to target wound healing as it was a key area of demand identified in our market research (through the ICURe programme) and includes diabetic ulcers, pressure ulcers, burns, wounds, and chronic non-healing ulcers; however, ANGICYTE can also be applied to other vascular diseases in the heart, brain, and limbs, and this will be the focus of our second phase. This Innovate UK grant will provide much needed start-up funding to allow us to spin out our company, develop our technology into a clinical grade product and meet with regulatory agencies that will guide the future development of these stem cells to effectively treat patients."

“VascVersa（用于再生医学的多功能血管干细胞）心血管疾病是全球死亡的首要原因。迫切需要找到新的治疗方法来修复受损的血管，因为目前的方法不是最佳的。在VascVersa，我们致力于开发创新的再生医学，我们已经优化了从血液样本中制造高纯血管干细胞的一致方法。我们独特的生成方法生产出一种干细胞治疗产品ANGICYTE，与其他可用的细胞产品相比，具有更高的纯度和上级生长能力。这些血管干细胞可以在我们的实验室中生长，以提供大量的治疗。由于所有组织修复都需要血液供应，ANGICYTE可以用于靶向血管损伤区域并促进受损血管的修复。我们有实验证据表明，我们的血管干细胞可用作促进新血管形成的细胞疗法。我们正在开发一种用于再生医学的新型细胞治疗产品ANGICYTE。在第一阶段，我们将使用ANGICYTE针对伤口愈合，因为这是我们市场研究（通过ICURe计划）中确定的关键需求领域，包括糖尿病溃疡，压疮，烧伤，伤口和慢性非愈合性溃疡;然而，ANGICYTE也可以应用于心脏，大脑和四肢的其他血管疾病，这将是我们第二阶段的重点。这项创新英国赠款将提供急需的启动资金，使我们能够分拆我们的公司，将我们的技术开发成临床级产品，并与监管机构会面，指导这些干细胞的未来发展，以有效地治疗患者。"